Superstring Capital Management’s Summit Therapeutics SMMT Stock Holding History

Superstring Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-892,873	Closed	-$16.9M	–	39
2026 Q1	$16.9M	Buy	+892,873	New	+$14.4M	12.09%	1
2025 Q4	–	Sell	-197,253	Closed	-$4.08M	–	59
2025 Q3	$4.08M	Buy	+197,253	New	+$4.78M	4.01%	10
2025 Q2	–	Sell	-132,019	Closed	-$2.55M	–	45
2025 Q1	$2.55M	Sell	132,019 -32,545	-20%	-$653K	3.03%	13
2024 Q4	$2.94M	Buy	+164,564	New	+$3.19M	2.54%	11

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Superstring Capital Management's SMMT Position: Q2 2026 in Review

Superstring Capital Management sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 892,873 shares — an estimated $16.9M sold.

Superstring Capital Management first reported a position in SMMT in Q4 2024 and held it in 4 quarters. The position peaked at $16.9M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Superstring Capital Management reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Superstring Capital Management sold 892,873 Summit Therapeutics shares in Q2 2026, an estimated $16.9M.
Superstring Capital Management first reported a position in Summit Therapeutics in Q4 2024 and held it in 4 quarters.
Superstring Capital Management's Summit Therapeutics position peaked at $16.9M in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.